Global Hematologic Malignancies Detection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Hematologic Malignancies Detection Market Research Report 2024
Hematological malignancy is a major disease that seriously endangers human health. With the invention and application of polymerase chain reaction, immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization, its overall diagnostic level has been significantly improved.
According to MRAResearch’s new survey, global Hematologic Malignancies Detection market is projected to reach US$ 5801.1 million in 2033, increasing from US$ 2234.7 million in 2022, with the CAGR of 14.6% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hematologic Malignancies Detection market research.
Increasing prevalence of hematological malignancies, emerging new technologies and methods for testing, patient preference for testing treatments, and increasing regulation across the healthcare industry are the key factors driving the growth of hematological malignancies testing market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Hematologic Malignancies Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics
Segment by Type
Polymerase Chain Reaction
Immunochemistry
Next Generation Sequencing
Fluorescence in Situ Hybridization
Others
Multiple Myeloma
Myelodysplastic Syndrome
Leukemia
Myeloproliferative Neoplasms
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hematologic Malignancies Detection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Hematologic Malignancies Detection market is projected to reach US$ 5801.1 million in 2033, increasing from US$ 2234.7 million in 2022, with the CAGR of 14.6% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hematologic Malignancies Detection market research.
Increasing prevalence of hematological malignancies, emerging new technologies and methods for testing, patient preference for testing treatments, and increasing regulation across the healthcare industry are the key factors driving the growth of hematological malignancies testing market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Hematologic Malignancies Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics
Segment by Type
Polymerase Chain Reaction
Immunochemistry
Next Generation Sequencing
Fluorescence in Situ Hybridization
Others
Segment by Application
Multiple Myeloma
Myelodysplastic Syndrome
Leukemia
Myeloproliferative Neoplasms
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hematologic Malignancies Detection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source